Drug-induced liver injury: what was new in 2013?

Bibliography

• Pyrsopoulos NT. editor. Drug Hepatotoxicity. Clin Liver Dis 2013;17(4):507-786
   PubMedGoogle Scholar
• Kaplowitz N, DeLeve LD. editors. Drug-induced liver disease. 3rd edition. Elsevier/Academic Press; London: 2013. p. 746; pages
   Google Scholar
• Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther 2013;37(1):3-17
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Seeff LB. Liver injury induced by herbal complementary and alternative medicine. Clin Liver Dis 2013;17(4):715-35
   PubMed Web of Science ®Google Scholar
• FDA Consumer Update. OxyElite Pro Supplements Recalled. 2013. Available from: http://www.fda.gov/forconsumers/consumerupdates/ucm374742.htm [Accessed 5 January 2014]
   Google Scholar
• Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis – a practical guide. Aliment Pharmacol Ther 2013;37:1132-56
   PubMed Web of Science ®Google Scholar
• Lewis JH. Drug-induced liver injury throughout the drug development life cycle: where we have been, where we are now, and where we are headed. Perspectives of a clinical hepatologist. Pharm Med 2013;27:165-91
   Google Scholar
• Pollock NR, Colby D, Rolland JP. A point-of-care paper-based fingerstick transaminase test: toward low-cost “lab-on-a-chip” technology for the developing world. Clin Gastroenterol Hepatol 2013;11(5):478-82
   PubMed Web of Science ®Google Scholar
• Pollock NR, McGray S, Colby DJ, et al. Field evaluation of a prototype paper-based point-of-care fingerstick transaminase test. PLoS One 2013;8(9):e75616
   PubMedGoogle Scholar
• Zhou Y, Yang L, Liao Z, et al. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol 2013;25(7):825-9
   PubMed Web of Science ®Google Scholar
• Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 2009;15(7):719-29
   PubMed Web of Science ®Google Scholar
• Lai RT, Wang H, Gui HL, et al. Clinical and pathological features in 138 cases of drug-induced liver injury. Zhonghua Gan Zang Bing Za Zhi 2012;20(3):185-9
   PubMedGoogle Scholar
• Wai CT. Presentation of drug-induced liver injury in Singapore. Singapore Med J 2006;47(2):116-20
   PubMedGoogle Scholar
• Sistanizad M, Peterson GM. Drug-induced liver injury in the Australian setting. J Clin Pharm Ther 2013;38(2):115-20
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013;144(7):1419-25
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Navarro VJ. Drug-induced liver injury: icelandic lessons. Gastroenterology 2013;144(7):1335-6
   PubMed Web of Science ®Google Scholar
• Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36(2):451-5
   PubMed Web of Science ®Google Scholar
• Sembera S, Lammert C, Talwalkar JA, et al. Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl 2012;18(7):803-10
   PubMed Web of Science ®Google Scholar
• Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf 2013;36(2):135-44
   PubMed Web of Science ®Google Scholar
• Ghabril M, Fontana R, Rockey D, et al. Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience. J Clin Gastroenterol 2013;47(6):553-8
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Chalasani NP, Lee WM, Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014;59(2):661-70
   PubMed Web of Science ®Google Scholar
• Lindquist M. Use of triage strategies in the WHO signal-detection process. Drug Saf 2007;30(7):635-7
   PubMed Web of Science ®Google Scholar
• Suzuki A, Andrade RJ, Bjornsson E, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010;33(6):503-22
   PubMed Web of Science ®Google Scholar
• Aagaard L, Strandell J, Melskens L, et al. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™. Drug Saf 2012;35(12):1171-82
   PubMed Web of Science ®Google Scholar
• Petronijevic M, Ilic K. Associations of gender and age with the reporting of drug-induced hepatic failure: data from the VigiBase™. J Clin Pharmacol 2013;53(4):435-43
   PubMed Web of Science ®Google Scholar
• Strandell J, Norén GN, Hägg S. Key elements in adverse drug interaction safety signals: an assessment of individual case safety reports. Drug Saf 2013;36(1):63-70
   PubMed Web of Science ®Google Scholar
• Brinker AD, Lyndly J, Tonning J, et al. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database. Drug Saf 2013;36(12):1169-78
   PubMed Web of Science ®Google Scholar
• Lee T, Lee YS, Yoon SY, et al. Characteristics of liver injury in drug-induced systemic hypersensitivity reactions. J Am Acad Dermatol 2013;69(3):407-15
   PubMed Web of Science ®Google Scholar
• Corsini A, Bortolini M. Drug-induced liver injury: the role of drug metabolism and transport. J Clin Pharmacol 2013;53(5):463-74
   PubMed Web of Science ®Google Scholar
• Stine JG, Sateesh P, Lewis JH. Drug-induced liver injury in the elderly. Curr Gastroenterol Rep 2013;15:299
   PubMedGoogle Scholar
• Begriche K, Massart J, Robin MA, et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 2013;58(4):1497-507
   PubMed Web of Science ®Google Scholar
• Fromenty B. Drug-induced liver injury in obesity. J Hepatol 2013;58(4):824-6
   PubMed Web of Science ®Google Scholar
• Gupta NK, Lewis JH. Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther 2008;28(9):1021-41
   PubMed Web of Science ®Google Scholar
• Stine JG, Lewis JH. Hepatotoxicity of Antibiotics: a Review and Update for the Clinician. Clin Liver Dis 2013;17(4):609-42
   PubMed Web of Science ®Google Scholar
• Lewis JH. Clinical perspective: statins and the liver – harmful or helpful? Dig Dis Sci 2012;57:1754-63
   PubMed Web of Science ®Google Scholar
• Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008;47(6):2003-9
   PubMed Web of Science ®Google Scholar
• Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010;51(2):615-20
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Idiosyncratic Drug Reactions: current Understanding. Annu Rev Pharmacol Toxicol 2007;513-39
   PubMed Web of Science ®Google Scholar
• Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013;58(1):388-96
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. Avoiding Idiosyncratic DILI: two is better than one. Hepatology 2013;58(1):15-17
   PubMed Web of Science ®Google Scholar
• Daly AK. Pharmacogenomics of adverse drug reactions. Genome Med 2013;5(1):5
   PubMedGoogle Scholar
• Alfirevic A, Pirmohamed M. Predictive genetic testing for drug-induced liver injury: considerations of clinical utility. Clin Pharmacol Ther 2012;Sep;92(3):376-80
   PubMed Web of Science ®Google Scholar
• Zhang FR, Liu H, Irwanto A, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 2013;369(17):1620-8
   PubMed Web of Science ®Google Scholar
• Watkins PB. Managing the risk of drug-induced liver injury. Clin Pharmacol Ther 2013;94(6):629-31
   PubMed Web of Science ®Google Scholar
• Markova SM, De Marco T, Bendjilali N, et al. Association of CYP2C9*2 with Bosentan-induced liver injury. Clin Pharmacol Ther 2013;94(6):678-86
   PubMed Web of Science ®Google Scholar
• Hawkins MT, Lewis JH. Latest advances in predicting DILI in human subjects: focus on biomarkers. Expert Opin Drug Metab Toxicol 2012;8(12):1521-30
   PubMed Web of Science ®Google Scholar
• Antoine DJ. Are we closer to finding biomarkers for identifying acute drug-induced liver injury? Biomarkers Med 2013;7(3):383-6
   PubMed Web of Science ®Google Scholar
• Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 2009;13(1):1-9
   PubMed Web of Science ®Google Scholar
• Overby CL, Pathak J, Gottesman O, et al. A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury. J Am Med Inform Assoc 2013;Dec;20(e2):e243-52
   PubMed Web of Science ®Google Scholar
• Aubrecht J, Schomaker SJ, Amacher DE. Emerging hepatotoxicity biomarkers and their potential to improve understanding and management of drug-induced liver injury. Genome Med 2013;5(9):85
   PubMedGoogle Scholar
• Schomaker S, Warner R, Bock J, et al. Assessment of emerging biomarkers of liver injury in human subjects. Toxicol Sci 2013;132(2):276-83
   PubMed Web of Science ®Google Scholar
• Steuerwald NM, Foureau DM, Norton HJ, et al. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One 2013;8(12):e81974
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013;58(2):777-87
   PubMed Web of Science ®Google Scholar
• Liss G, Rattan S, Lewis JH. Predicting and preventing drug-induced liver injury: what's new in 2010? Expert Opin Drug Metab Toxicol 2010;6(9):1-15
   PubMedGoogle Scholar
• Stine J, Lewis JH. Drug induced liver injury : a summary of recent advances. Expert Opin Drug Metab Toxicol 2011;7(7):1-16
   PubMedGoogle Scholar
• Andrews S, Holden R. Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res 2012;4:299-307
   PubMedGoogle Scholar
• Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368(14):1365-6
   PubMed Web of Science ®Google Scholar
• Bernardo SG, Moskalenko M, Pan M, et al. Elevated rates of elevated aminotransferases during ipilimumab therapy for metastatic melanoma. Melanoma Res 2013;23(1):47-54
   PubMed Web of Science ®Google Scholar
• Sharma A, Thompson JA, Repaka A, Mehnert JM. Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. J Clin Oncol 2013;20;31(21):e370-2
   PubMed Web of Science ®Google Scholar
• Kim KW, Ramaiya NH, Krajewski KM. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013;31(4):1071-7
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 2012;57(8):2233-40
   PubMed Web of Science ®Google Scholar
• Felser A, Blum K, Lindinger PW, et al. Mechanisms of hepatocelluar toxicity associated with dronedarone—a comparison to amiodarone. Toxicol Sci 2013;131(2):480-90
   PubMed Web of Science ®Google Scholar
• Joghetaei N, Weirich G, Huber W, et al. Acute liver failure associated with dronedarone. Circ Arrhythm Electrophysiol 2011;4(4):592-3
   PubMed Web of Science ®Google Scholar
• Jahn S, Zollner G, Lackner C, Stauber RE. Severe toxic hepatitis associated with dronedarone. Curr Drug Saf 2013;8(3):201-2
   PubMedGoogle Scholar
• Nemerovski C, Hutchinson DJ. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review. Clin Ther 2010;32(6):1015-32
   PubMed Web of Science ®Google Scholar
• Erickson KF, Chertow GM, Goldhaber-Fiebert JD. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med 2013;159(6):382-9
   PubMed Web of Science ®Google Scholar
• Pittman D. FDA panel vetoes new tovaptan indication. Available from: http://www.medpagetoday.com/Nephrology/GeneralNephrology/40844 0 [Accessed 14 March 2014]
   Google Scholar
• Torres VE, Chapman AB, Devuyst O, Gansevoort RT. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367(25):2407-18
   PubMed Web of Science ®Google Scholar
• Mirski D. Important Drug Warning. Potential risk of liver injury with use of SAMSCA® (tolvaptan). Otsuka America Pharmaceuticals, Inc., Princeton, NJ; 2013
   Google Scholar
• Miyazaki T, Fujiki H, Yamamura Y. Tolvaptan, an orally active non-peptide arginine vasopressin V2 receptor antagonist, reduces ascites in rats with chronic liver injury. Hepatol Res 2013
   Web of Science ®Google Scholar
• Shu CC, Lee CH, Lee MC, et al. Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis 2013;17(7):934-9
   PubMed Web of Science ®Google Scholar
• Devarbhavi H, Singh R, Patil M, et al. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol 2013;28(1):161-7
   PubMed Web of Science ®Google Scholar
• Hassen Ali A, Belachew T, Yami A, Ayen WY. Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study. PLoS One 2013;8(5):e64622
   PubMed Web of Science ®Google Scholar
• James L, Roberts D. Isoniazid hepatotoxicity: progress in understanding the immunologic component. Hepatology 2014;59(3):746-8
   PubMed Web of Science ®Google Scholar
• Metushi IG, Sanders C; Acute Liver failure Study GroupLee WM, Uetrecht J. Detection of anti-isoniazid and anti-CYP antibodies in patients with isoniazid-induced liver failure. Hepatology 2014;59(3):1084-93
   PubMed Web of Science ®Google Scholar
• Tang SW, Lv XZ, Chen R, et al. Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population. Clin Exp Pharmacol Physiol 2013;40(5):326-32
   PubMed Web of Science ®Google Scholar
• Tang S, Lv X, Zhang Y, et al. Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort. PLoS One 2013;8(2):e57526
   PubMed Web of Science ®Google Scholar
• Kao WY, Su CW, Huang YS, Chou YC. Risk of oral anti-fungal agent-induced liver injury in Taiwanese. Br J Clin Pharmacol 2014;77(1):180-9
   PubMed Web of Science ®Google Scholar
• Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag 2005;1(4):299-306
   PubMedGoogle Scholar
• FDA advises against using oral ketoconazolein drug interaction studies due to serious potential side effects 10/16/2013. Available from: http://www.fda.gov/drugs/drugsafety/ucm371017.htm [Accessed 21 March 2014]
   Google Scholar
• Iacovelli R, Palazzo A, Procopio G, et al. Incidence and relative risk of hepatic toxicity in patients treated with antiangiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol 2013. [ Epub ahead of print]
   Google Scholar
• Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013;36(7):491-503
   PubMed Web of Science ®Google Scholar
• Teo YL, Ho HK, Chan A. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev 2013;39(2):199-206
   PubMed Web of Science ®Google Scholar
• Spraggs CF, Parham LR, Hunt CM, Dollery CT. Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes. Clin Pharmacol Ther 2012;91(4):647-52
   PubMed Web of Science ®Google Scholar
• Teschke R, Wolff A, Frenzel C, et al. Herbal hepatotoxicity: a tabular compilation of reported cases. Liver Int 2012;32(10):1543-56
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Notes from the field: acute hepatitis and liver failure following the use of a dietary supplement intended for weight loss or muscle building--May-October 2013. MMWR Morb Mortal Wkly Rep 2013;11;62(40):817-19
   PubMedGoogle Scholar
• Kuehn BM. Dietary supplement linked to cases of acute hepatitis. JAMA 2013;310(17):1784
   PubMed Web of Science ®Google Scholar
• Teschke R, Schulze J. Suspected herbal hepatotoxicity: requirements for appropriate causality assessment by the US Pharmacopeia. Drug Saf 2012;35(12):1091-7
   PubMed Web of Science ®Google Scholar
• Teschke R, Schulze J, Schwarzenboeck A, et al. Herbal hepatotoxicity: suspected cases assessed for alternative causes. Eur J Gastroenterol Hepatol 2013; 25(9):1093-8
   PubMed Web of Science ®Google Scholar
• Teschke R, Schwarzenboeck A, Eickhoff A, et al. Clinical and causality assessment in herbal hepatotoxicity. Expert Opin Drug Saf 2013;12(3):339-66
   PubMed Web of Science ®Google Scholar
• Teschke R, Eickhoff A, Wolff A, et al. Herbal hepatotoxicity and WHO global introspection method. Ann Hepatol 2013;12(1):11-21
   PubMed Web of Science ®Google Scholar
• Teschke R, Frenzel C, Schulze J, et al. Herbalife hepatotoxicity: evaluation of cases with positive reexposure tests. World J Hepatol 2013 5(7):353-63
   PubMedGoogle Scholar
• Teschke R, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. World J Gastroenterol 2013;19(19):2864-82
   PubMed Web of Science ®Google Scholar
• Teschke R, Sarris J, Lebot V. Contaminant hepatotoxins as culprits for kava hepatotoxicity--fact or fiction? Phytother Res 2013;27(3):472-4
   PubMed Web of Science ®Google Scholar
• Wallimann T. Comment on “toxic hepatitis in a group of 20 male body-builders taking dietary supplements” by. Food Chem Toxicol 2013;51:453-4
   PubMed Web of Science ®Google Scholar
• Timcheh-Hariri A, Balali-Mood M, Aryan E, et al. Toxic hepatitis in a group of 20 male body-builders taking dietary supplements. Food Chem Toxicol 2012;50(10):3826-32
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Bonkovsky HL, Hwang SI, et al. Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci 2013;58(9):2682-90
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: completed safety review of Xenical/Alli (orlistat) and severe liver injury. 2010. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm [Accessed 3 January 2014]
   Google Scholar
• Morris M, Lane P, Lee K, Parks D. An integrated analysis of liver safety data from orlistat clinical trials. Obes Facts 2012;5(4):485-94
   PubMed Web of Science ®Google Scholar
• Douglas IJ, Langham J, Bhaskaran K, et al. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ 2013;346:f1936
   PubMed Web of Science ®Google Scholar
• Wilding J. Orlistat: should we worry about liver inflammation? BMJ 2013;346:f2777
   PubMedGoogle Scholar
• Lee WM. Drug-induced acute liver failure. Clin Liver Dis 2013;17(4):575-86
   PubMed Web of Science ®Google Scholar
• Bunchorntavakul C, Reddy KR. Acetaminophen-related hepatotoxicity. Clin Liver Dis 2013;17(4):587-60
   PubMed Web of Science ®Google Scholar
• Hawton K, Bergen H, Simkin S, et al. Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ 2013;346:f403
   PubMed Web of Science ®Google Scholar
• Hawton K, Bergen H, Simkin S, et al. Impact of different pack sizes of paracetamol in the United Kingdom and Ireland on intentional overdoses: a comparative study. BMC Public Health 2011;11:460
   PubMed Web of Science ®Google Scholar
• Hawton K, Bergen H, Simkin S, et al. Six-year follow-up of impact of co-proxamol withdrawal in England and Wales on prescribing and deaths: time-series study. PLoS Med 2012;9(5):e1001213
   PubMedGoogle Scholar
• McGill MR, Jaeschke H. Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharm Res 2013;30(9):2174-87
   PubMed Web of Science ®Google Scholar
• Green JL, Heard KJ, Reynolds KM, Albert D. Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: a systematic review and meta-analysis. West J Emerg Med 2013;14(3):218-26
   PubMedGoogle Scholar
• McGill MR, Lebofsky M, Norris HR, et al. Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: dose-response, mechanisms, and clinical implications. Toxicol Appl Pharmacol 2013;269(3):240-9
   PubMed Web of Science ®Google Scholar
• James LP, Chiew A, Abdel-Rahman SM, et al. Acetaminophen protein adduct formation following low-dose acetaminophen exposure: comparison of immediate-release vs extended-release formulations. Eur J Clin Pharmacol 2013;69(4):851
   PubMed Web of Science ®Google Scholar
• Leonis MA, Alonso EM, Im K, et al. Chronic acetaminophen exposure in pediatric liver failure. Pediatrics 2013;131(3):e740-6
   PubMed Web of Science ®Google Scholar
• Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. US drug-induced liver injury network. Clin Gastroenterol Hepatol 2013;11(5):558-64
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Hayashi P, Bonkovsky HL, et al. Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig Dis Sci 2013;58(6):1766-75
   PubMed Web of Science ®Google Scholar
• Lee YH, Song GG. Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension. Korean J Intern Med 2013;28(6):701-7
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang J, Wang Y, et al. The liver toxicity knowledge base: a systems approach to a complex end point. Clin Pharmacol Ther 2013;93(5):409-12
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ. LiverTox: a website on drug-induced liver injury. Hepatology 2013;57(3):873-4
   PubMed Web of Science ®Google Scholar
• Wang B, Avorn J, Kesselheim AS. Clinical and regulatory features of drugs not initially approved by the FDA. Clin Pharmacol Ther 2013;94(6):670-7
   PubMed Web of Science ®Google Scholar
• Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001;286(7):831-3
   PubMed Web of Science ®Google Scholar
• Singh S, Hynan LS, Lee WM; Acute Liver Failure Study Group. Improvements in hepatic serological biomarkers are associated with clinical benefits of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci 2013;58(5):1397-402
   PubMed Web of Science ®Google Scholar
• Lee WM, Hynan LS, Rossaro L, Acute Liver Failure Study Group. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastro 2009;137(3):856-64. 864.e1
   PubMed Web of Science ®Google Scholar
• Sales I, Dzierba AL, Smithburger PL, et al. Use of acetylcysteine for non-acetaminophen-induced acute liver failure. Ann Hepatol 2013;12(1):6-10
   PubMed Web of Science ®Google Scholar
• Innovative Medicines Initiative. Available from: http://www.imi.europa.eu [Accessed 14 March 2014]
   Google Scholar
• US Food and Drug Administration. Guidance for industry. Clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM337169.pdf [Accessed January 2013]
   Google Scholar
• Stephens C, López-Nevot MÁ, Ruiz-Cabello F, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One 2013;8(7):e68111
   PubMed Web of Science ®Google Scholar
• Vera JH, Naous N, Mackie N, et al. The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype. AIDS 2013;27(3):484-5
   PubMed Web of Science ®Google Scholar
• Wuillemin N, Adam J, Fontana S, et al. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. J Immunol 2013;190(10):4956-64
   PubMed Web of Science ®Google Scholar
• Elsharkawy AM, Schwab U, McCarron B, et al. Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser. J Clin Virol 2013;58(1):331-3
   PubMed Web of Science ®Google Scholar
• Kaniwa N, Saito Y. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. J Hum Genet 2013;58(6):317-26
   PubMed Web of Science ®Google Scholar
• Hagleitner MM, Coenen MJ, Aplenc R, et al. The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. Pharmacogenomics J 2014;14(2):115-19
   PubMed Web of Science ®Google Scholar
• Takimoto T, Kijima T, Otani Y, et al. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity. Clin Lung Cancer 2013;14(5):502-7
   PubMed Web of Science ®Google Scholar
• Gupta VH, Amarapurkar DN, Singh M, et al. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol 2013;28(8):1368-74
   PubMed Web of Science ®Google Scholar
• Ho HT, Wang TH, Hsiong CH, et al. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics 2013;23(4):200-7
   PubMed Web of Science ®Google Scholar
• Li C, Long J, Hu X, Zhou Y. GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis. Eur J Clin Microbiol Infect Dis 2013;32(7):859-68
   PubMed Web of Science ®Google Scholar
• Chamorro JG, Castagnino JP, Musella RM, et al. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol 2013;28(2):323-8
   PubMed Web of Science ®Google Scholar
• Hymel BM, Victor DW, Alvarez L, et al. Mastabol induced acute cholestasis: a case report. World J Hepatol 2013;5(3):133-6
   PubMedGoogle Scholar
• Eriksson C, Gustavsson A, Kronvall T, Tysk C. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointestin Liver Dis 2011;Mar;20(1):77-80
   PubMed Web of Science ®Google Scholar
• Douros A, Kauffmann W, Bronder E, et al. Ramipril-induced liver injury: case report and review of the literature. Am J Hypertens 2013;26(9):1070-5
   PubMed Web of Science ®Google Scholar
• El Sherrif Y, Potts JR, Howard MR, et al. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations? Liver Int 2013;33(8):1266-70
   PubMed Web of Science ®Google Scholar
• Makhani N, Ngan BY, Kamath BM, Yeh EA. Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS. Neurology 2013;81(9):850-2
   PubMed Web of Science ®Google Scholar
• Suen CF, Boyapati R, Simpson I, Dev A. Acute liver injury secondary to sertraline. BMJ Case Rep 2013. [ Epub ahead of print]
   Google Scholar
• Nasser M, Larsen TR, Waanbah B, et al. Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature. Drug Healthc Patient Saf 2013;5:191-8
   Google Scholar